We postulate that, because dopamine and serotonin both mediate schizophrenia symptoms and underlie the reinforcing effects of cocaine, the use of cocaine among individuals with schizophrenia may ...
OPC-4392 was shown to be effective against negative symptoms and showed no propensity to induce extrapyramidal symptoms in individuals with schizophrenia ... isoforms of the dopamine receptors ...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
Genetics constitute a crucial risk factor to schizophrenia. In the last decade, molecular genetic research has produced novel findings, infusing optimism about discovering the biological roots of ...
Dopamine is an inotropic agent that has vasodilatory effects at low doses. It is a common belief that low-dose dopamine may be helpful in the prevention and treatment of acute renal failure and is ...
If it does prove to be the end of emraclidine for schizophrenia ... Cerevel's pipeline behind emraclidine includes tavapadon, a dopamine D1/D5 partial agonist in phase 3 testing as a treatment ...
the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but NBI-1117568 is one of a series of new therapies emerging from the pharma industry pipeline ...
Time blindness is a cognitive condition that affects an individual's ability to perceive and manage time, often linked to ADHD. Those with the conditi ...
Schizophrenia is a disorder with a heterogeneous etiology involving complex interplay between genetic and environmental risk factors. The immune system is now known to play vital roles in nervous ...